Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

867
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
867
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

1.6K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
1.6K
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists01:29

Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists

733
Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
733
Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists01:28

Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists

1.1K
Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...
1.1K
Direct-Acting Cholinergic Agonists: Therapeutic Uses01:11

Direct-Acting Cholinergic Agonists: Therapeutic Uses

1.4K
Direct-acting cholinergic agonists have many therapeutic uses in various medical fields. Choline esters, including acetylcholine, have limited clinical utility due to their non-selectivity and short duration of action. Still, acetylcholine and carbachol are applied topically during ophthalmologic surgery to induce miosis. Pilocarpine, a muscarinic and ganglionic stimulator, effectively treats open-angle glaucoma and alleviates xerostomia and dry mouth caused by radiotherapy or Sjögren...
1.4K
Drugs Affecting Neurotransmitter Synthesis01:29

Drugs Affecting Neurotransmitter Synthesis

2.0K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
2.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A video-atlas of levodopa-induced dyskinesia in Parkinson's disease: terminology matters.

Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology·2023
Same author

Incidental complex repetitive discharges on needle electromyography.

Muscle & nerve·2022
Same author

Exploring essential tremor: Results from a large online survey.

Clinical parkinsonism & related disorders·2022
Same author

The Pseudodystonia of Paroxysmal Sympathetic Hyperactivity: A Reversible Post-Anoxic Complication.

Movement disorders clinical practice·2021
Same author

Cardiology perspective on seizure-related bradyarrhythmias and SUDEP: A survey study.

Epilepsy & behavior : E&B·2021
Same author

Clinicopathological Correlation: Dopamine and Amyloid PET Imaging with Neuropathology in Three Subjects Clinically Diagnosed with Alzheimer's Disease or Dementia with Lewy Bodies.

Journal of Alzheimer's disease : JAD·2021
Same journal

A Prospective Study on Autonomic Functions in Idiopathic Inflammatory Myopathies: The AFIIM Study.

Annals of Indian Academy of Neurology·2026
Same journal

Efficacy of Sodium Phenylbutyrate-Taurursodiol in Amyotrophic Lateral Sclerosis: A Systematic Review and Meta-Analysis.

Annals of Indian Academy of Neurology·2026
Same journal

High Titers, Hidden Disease: Asymptomatic Neurosyphilis in Secondary Syphilis - A Case Series from Western Maharashtra.

Annals of Indian Academy of Neurology·2026
Same journal

Development of a Composite Clinicopathological Scoring System for Enhancing Diagnostic Accuracy of Vasculitic Neuropathy: A Pilot Study.

Annals of Indian Academy of Neurology·2026
Same journal

Deep Learning Detection of Facial Nerve Enhancement in Bell's Palsy.

Annals of Indian Academy of Neurology·2026
Same journal

A Study on the Spectrum of Autonomic Dysfunction in Primary Central Nervous System Demyelinating Disorders in a Tertiary Care Center from Eastern India.

Annals of Indian Academy of Neurology·2026
See all related articles

Related Experiment Video

Updated: Dec 26, 2025

Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease
05:51

Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease

Published on: October 14, 2021

4.3K

Levodopa-Responsive Chorea: A Review.

Mark Farrenburg1, Harsh V Gupta1

  • 1Department of Neurology, Kansas University Medical Center, Kansas City, Kansas, USA.

Annals of Indian Academy of Neurology
|March 20, 2020
PubMed
Summary
This summary is machine-generated.

Levodopa may improve chorea in brain-thyroid-lung (BTL) syndrome, but its effectiveness in other chorea types requires more research. This review explores levodopa

Keywords:
Choreahereditary choreahuntington diseaselevodopa

More Related Videos

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease
06:45

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease

Published on: October 4, 2021

3.2K
Primary Culture of Mouse Dopaminergic Neurons
11:58

Primary Culture of Mouse Dopaminergic Neurons

Published on: September 8, 2014

39.0K

Related Experiment Videos

Last Updated: Dec 26, 2025

Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease
05:51

Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease

Published on: October 14, 2021

4.3K
Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease
06:45

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease

Published on: October 4, 2021

3.2K
Primary Culture of Mouse Dopaminergic Neurons
11:58

Primary Culture of Mouse Dopaminergic Neurons

Published on: September 8, 2014

39.0K

Area of Science:

  • Neurology
  • Movement Disorders
  • Pharmacology

Background:

  • Chorea is a disabling movement disorder with limited effective treatment options.
  • Current FDA-approved treatments for chorea associated with Huntington's Disease (HD) include tetrabenazine and deutetrabenazine.
  • Levodopa's potential to alleviate chorea in certain conditions warrants investigation.

Purpose of the Study:

  • To review the existing literature on the use of levodopa for treating chorea.
  • To gather information on the efficacy, dosage, and outcomes of levodopa in various chorea etiologies.

Main Methods:

  • A comprehensive literature search was conducted in February 2019.
  • Search terms included 'levodopa chorea,' 'levodopa TITF-1,' 'levodopa brain-lung-thyroid syndrome,' and 'levodopa Huntington's Disease.'
  • Data on etiology, treatment outcomes, and levodopa dosage were extracted from identified studies.

Main Results:

  • A total of 18 cases reported benefits from levodopa treatment for chorea.
  • Brain-thyroid-lung (BTL) syndrome accounted for the majority (50%) of responsive cases.
  • Other reported conditions included Huntington's Disease, Pontocerebellar hypoplasia type 2, meningovascular syphilis, and Sydenham chorea, with BTL syndrome patients responding to low levodopa doses.

Conclusions:

  • Levodopa shows potential for improving chorea in BTL syndrome, particularly that linked to NKX2-1 mutations.
  • Further research is needed to establish levodopa's efficacy in chorea caused by other disorders.
  • No cases of chorea due to ADCY-5 mutation responding to levodopa were identified.